Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9223260 | 0.83 | MAPT (0.47) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6429442 | 0.82 | GRIA2 (0.46) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Gyki-52466 SCHEMBL194854 | 0.81 | GRIA2 (1.00) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Gyki-52466 SCHEMBL29357520 | 0.81 | GRIA2 (1.00) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Gyki-52466 SCHEMBL25227675 | 0.80 | LMNA (1.00) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Gyki-52466 SCHEMBL29651319 | 0.80 | LMNA (1.00) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Gyki-52466 SCHEMBL249675 | 0.80 | LMNA (1.00) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8793015 | 0.78 | MAPT (0.43) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8793158 | 0.78 | ALDH1A1 (0.43) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7399020 | 0.77 | KMT2A (0.42) | GRIA2CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255798-B1 | FTY720 for use in the treatment of optic neuritis | NOVARTIS AG (CH) | 2014-12-24 | — | — | EP | claimed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-4252849-A2 | DEPOT SYSTEMS COMPRISING GLATIRAMER ACETATE | Mapi Pharma Ltd. (IL) | 2023-10-04 | — | — | EP | disclosed |
| EP-3506921-B1 | DEPOT SYSTEMS COMPRISING GLATIRAMER ACETATE | MAPI PHARMA LTD (IL) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023042888-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING COGNITIVE DECLINE OR FOR TREATING OVERWEIGHTNESS OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023042887-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING COGNITIVE DECLINE, EXCESS WEIGHT, OR OBESITY | 国立大学法人 琉球大学 | 2023-03-23 | — | — | WO | disclosed |
| EP-3536333-B1 | DEPOT SYSTEM COMPRISING GLATIRAMER ACETATE | MAPI PHARMA LTD (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20220023377-A1 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | MAPI PHARMA LTD. (IL) | 2022-01-27 | — | — | US | disclosed |
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| US-20030073683-A1 | Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury | BELAYEV LUDMILA (US) | 2003-04-17 | — | — | US | disclosed |
| US-5639751-A | N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders | CYOGYSZERKUTATO INTEZET KFT (HU) | 1997-06-17 | — | — | US | disclosed |
| US-5521174-A | ANTISPASMODIC AGENTS | GYOGYSZERKUTATO INTEZET KV. (HU) | 1996-05-28 | — | — | US | disclosed |
| US-5385903-A | Pharmaceutical agent for treatment of withdrawal symptoms | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | GRIA2 21/4885CYP1A2 4690/4885CYP3A4 4777/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | GRIA2 21/4885CYP1A2 4666/4885CYP3A4 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.